Erenumab For Treatment of Hemicrania Continua

Overview

About this study

The purposes of this study are to evaluate the response of hemicrania continua to treatment with erenumab, and to evaluate the safety and tolerability of erenumab in patients with hemicrania continua.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adults ages 18 and older.
At least a 12 month history of hemicrania continua (unremitting subtype) according to International Classification of Headache Disorders, 3rd Edition (ICHD-3)1.
Previous or current complete response to indomethacin.
Stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment.

Exclusion Criteria:

Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week.
Pregnant or lactating subjects.
Use of barbiturate or opioid > 6 days per month.
History of chronic migraine.
History of previous trigeminal-autonomic cephalalgia.
History within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy).
History of cranial nerve/rhizolysis.
Botulinumtoxin injection with previous 4 months
Parenteral infusion of an oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Rashmi Halker Singh, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Rashmi Halker Singh, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials